跳转至内容
Merck
CN

33999

利福昔明

VETRANAL®, analytical standard

别名:

4-脱氧-4′-甲基吡啶并[1′,2′-1,2]咪唑并[5,4-c]利福霉素 SV, 利福昔明

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C43H51N3O11
化学文摘社编号:
80621-81-4
分子量:
785.88
NACRES:
NA.24
PubChem Substance ID:
329754738
UNSPSC Code:
41116107
MDL number:
MFCD00864973

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

利福昔明, VETRANAL®, analytical standard

InChI

1S/C43H51N3O11/c1-19-14-16-46-27(18-19)44-32-29-30-37(49)25(7)39-31(29)40(51)43(8,57-39)56-17-15-26(54-9)22(4)28(42(53)55-10)23(5)36(48)24(6)35(47)20(2)12-11-13-21(3)41(52)45-33(34(32)46)38(30)50/h11-18,20,22-24,26,28,35-36,47-50H,1-10H3,(H,45,52)/b12-11+,17-15+,21-13-/t20-,22+,23-,24-,26+,28+,35-,36-,43+/m1/s1

SMILES string

CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(C)=C\C=C\[C@@H](C)[C@@H](O)[C@@H](C)[C@H](O)[C@H](C)[C@H]([C@H]1C)C(=O)OC)c5c(nc6cc(C)ccn56)c4c3C2=O

InChI key

HIYLTQREEOINNF-HTEWPBCCSA-N

grade

analytical standard

product line

VETRANAL®

shelf life

limited shelf life, expiry date on the label

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

forensics and toxicology
pharmaceutical (small molecule)

format

neat

Quality Level

100

正在寻找类似产品? 访问 产品对比指南

相关类别

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

General description

Chemical structure: macrolide

Legal Information

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

存储类别

11 - Combustible Solids

wgk

WGK 3

ppe

Eyeshields, Gloves, type N95 (US)

法规信息

涉药品监管产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
BCCL0490
BCCD4030
BCBT5109

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Gilbert G G Donders et al.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 120(2), 131-136 (2013-01-01)
To compare efficacy and tolerability between different regimens of rifaximin vaginal tablets and a placebo for treatment of bacterial vaginosis. In a prospective study carried out at 13 sites in 3 European countries between August 2009 and October 2010, White
Guy W Neff et al.
Journal of clinical gastroenterology, 47(2), 188-192 (2013-01-15)
The purpose of this study was to assess the incidence of Clostridium difficile infection in patients who received rifaximin for the treatment of hepatic encephalopathy (HE). Medical charts of patients who received rifaximin for the treatment of HE were reviewed.
Muna Qayed et al.
Journal of pediatric hematology/oncology, 35(4), e149-e152 (2013-01-01)
In murine allogeneic hematopoietic cell transplantation models, inhibiting bacterial translocation stemming from conditioning-induced damage to the gut mucosa abrogates inflammatory stimulation of donor T cells, preventing acute graft-versus-host disease (AGVHD). We conducted a phase I trial to begin testing the
Vishesh Kothary et al.
Antimicrobial agents and chemotherapy, 57(2), 811-817 (2012-11-28)
Escherichia coli is implicated in the pathogenesis of inflammatory bowel disease (IBD). Rifaximin, a nonabsorbable derivative of rifampin effective against E. coli, improves symptoms in mild-to-moderate IBD. However, rifaximin resistance can develop in a single step in vitro. We examined
Rosacea and small intestinal bacterial overgrowth: prevalence and response to rifaximin.
Leonard B Weinstock et al.
Journal of the American Academy of Dermatology, 68(5), 875-876 (2013-04-23)
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持